The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2021 | LCMC3 primary analysis: Neoadjuvant atezolizumab in NSCLC
Jay Lee, MD, UCLA Health, Los Angeles, CA, shares the highly anticipated clinical and surgical outcome results from the Phase III LCMC3 trial (NCT02927301) of pre-operative atezolizumab in untreated stage IB-IIIB resectable non-small cell lung cancer (NSCLC). In total, 181 patients were treated and followed-up post-surgery to assess major pathological response (MPR), defined as ≤10% viable tumor cells at surgery. The data showed that atezolizumab gave an MPR rate of 21%. The treatment was well tolerated, and rates of complete resection were high, with low occurrences of perioperative morbidity and mortality. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.
Disclosures
Advisory board: AstraZeneca, Bristol Myers Squibb, Genentech/Roche, Novartis
Consultancy: Genentech/Roche
Steering committee: Genentech/Roche, Novartis
Research support: Merck
